X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to support Crossject’s activities in bringing its Zepizure (midazolam), a short-acting hypnotic-sedative epileptic rescue therapy, to market.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Zepizure
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gemmes Venture
Deal Size: $8.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 04, 2024
Details:
Under the terms of the agreement, Crossject Zepizure (midazolam) will be commercialized in the European market for the treatment of epileptic seizures.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Zepizure
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 02, 2024
Details:
The financing aims to support the clinical development of Zepizure (midazolam), a short-acting hypnotic-sedative medication currently undergoing evaluation in patients for the treatment of epileptic seizures.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Zepizure
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Heights Capital Management
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 27, 2024
Details:
Under the agreement, Syneos Health will provide support in all pre-launch and launch activities for Zepizure (midazolam), an epileptic rescue therapy for epileptic seizures.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Zepizure
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Syneos Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 04, 2024
Details:
The agreement aims for the commercialization of Crossject's innovative rescue therapy for epileptic seizures Zepizure (midazolam), previously known as ZENEO® Midazolam, in northern Europe covering Germany, the UK, Denmark, Sweden, Finland and Norway.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Zepizure
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Agreement December 22, 2023
Details:
Under the agreement, AFT will commercialise ZENEO® Midazolam, a combination of the single use needle-free auto injector ZENEO® and the drug product midazolam, in epileptic seizures in Australia and New Zealand.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Zeneo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AFT Pharmaceuticals
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 20, 2023
Details:
ZENEO and the syringe with intramucular needle showed a similar and low inter-subject variability of midazolam pharmacokinetics. This is an additional demonstration that an injection with ZENEO reached muscle in the same way as an injection with a syringe and a 30 mm needle.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Zeneo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
ZENEO's Midazolam is developed as a combination of the single use needle-free auto injector ZENEO and the drug product midazolam, which is an improved anti-convulsant benzodiazepine recommended for treatment of strong seizures resulting from epilepsia.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Zeneo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Agreement June 18, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
